NasdaqGS:MAR
NasdaqGS:MARHospitality

Is Marriott International’s Strong 2025 Rally Justified by Its Cash Flow and Earnings Outlook?

If you are wondering whether Marriott International is still attractively valued at current levels or if much of the potential upside may already be reflected in the share price, this breakdown is designed to help you cut through the noise and focus on value. The stock has climbed 1.7% over the last week, 6.1% over the past month, and is up 14.3% year to date, following gains of 117.6% and 153.5% over the last 3 and 5 years respectively. Those moves sit against a backdrop of ongoing travel...
NYSE:ROL
NYSE:ROLCommercial Services

Is It Too Late To Consider Rollins After Strong 2025 Share Price Rally?

If you are wondering whether Rollins is still worth buying after its big run up, or if most of the upside is now priced in, you are not alone. This is exactly what we are going to unpack. The stock has climbed 1.9% over the last week, 1.4% over the past month, and is now up about 32.8% year to date and 33.0% over the last year, with longer term gains of 71.3% over 3 years and 67.7% over 5 years from a recent close of $61.14. Those returns come against a backdrop of steady demand for pest...
NasdaqGS:OPEN
NasdaqGS:OPENReal Estate

Opendoor (OPEN) Valuation Check After New Leadership Team Drives Speculation Around ‘Opendoor 2.0’ Strategy

Opendoor Technologies (OPEN) just refreshed its leadership bench by naming fintech veteran Lucas Matheson as president and elevating long time insider Christy Schwartz to CFO, a move squarely aimed at accelerating the company’s Opendoor 2.0 pivot. See our latest analysis for Opendoor Technologies. The leadership reshuffle caps a wild year in which Opendoor’s 2025 share price return has jumped roughly 300 percent, even as more recent share price performance has cooled and momentum looks more...
NasdaqGM:TRUP
NasdaqGM:TRUPInsurance

Trupanion (TRUP) Valuation After New Pawp Partnership, CEO Share Sale, and Strong Earnings Update

Trupanion (TRUP) is back in the spotlight after a busy stretch, from a new distribution partnership with Pawp Insurance Solutions to CEO Margaret Tooth’s recent stock sale and option exercise following better than expected earnings. See our latest analysis for Trupanion. Those moves land against a mixed backdrop, with Trupanion’s share price now at $38.05, a solid 1 month share price return but a weaker 1 year total shareholder return suggesting momentum is rebuilding from a still bruised...
NYSE:CCL
NYSE:CCLHospitality

Carnival (CCL) Is Up 12.6% After Record 2025 Results And Dividend Restart - What's Changed

Carnival Corporation & plc recently reported record full-year 2025 results, with revenue rising to US$26.62 billion and net income reaching US$2.76 billion, and the board approved reinstating a quarterly dividend of US$0.15 per share starting with a February 27, 2026 payment. The company also proposed unifying its dual-listed structure into a single Bermuda-incorporated entity listed on the NYSE, aiming to simplify governance, cut administrative costs, and potentially improve share liquidity...
NasdaqGM:IOVA
NasdaqGM:IOVABiotechs

Is Iovance (IOVA) Turning Talent Incentives and TIL Optimism Into a Durable Competitive Edge?

Iovance Biotherapeutics recently strengthened its position by granting inducement stock options to new employees while benefiting from fresh analyst coverage and renewed optimism toward its Amtagvi cell therapy and broader pipeline. This combination of talent incentives and improving sentiment around tumor-infiltrating lymphocyte therapies, including potential expansion into non-small cell lung cancer, is reframing how investors view the company’s long-term prospects. We’ll now explore how...
NYSE:QBTS
NYSE:QBTSSoftware

Can D-Wave Quantum’s (QBTS) CES 2026 Push Redefine Its Edge In Commercial Quantum Computing?

D-Wave Quantum recently announced plans to showcase its Advantage2 annealing quantum system and real-world customer use cases at CES 2026, highlighting growing commercial traction, expanding government initiatives, and fresh institutional interest. This combination of product availability, expanding use cases across industries, and bullish analyst coverage is reshaping how investors view the company’s commercialization timeline and competitive positioning in quantum computing. With D-Wave’s...
NYSE:MOH
NYSE:MOHHealthcare

Reassessing Molina Healthcare (MOH) Valuation as Legal Probe Puts 2025 Guidance and Cost Assumptions in Focus

Grabar Law Office has launched an investigation into Molina Healthcare (MOH), questioning whether management adequately disclosed rising medical cost trends and a mismatch between premiums and underlying costs, which has put the company’s 2025 financial guidance under sharper investor scrutiny. See our latest analysis for Molina Healthcare. The investigation is landing after a volatile stretch, with Molina’s share price at $163.68 following a strong 1 month share price return, but a steep...
NasdaqGS:HALO
NasdaqGS:HALOBiotechs

Does Halozyme Still Offer Value After a 44.5% Surge and Strong DCF Upside?

If you are wondering whether Halozyme Therapeutics at around $68 is still a smart buy, or if most of the upside is already priced in, you are not alone. This article is going to tackle that value question head on. The stock is up 7.4% over the last week and 42.0% year to date, even after a slightly softer 30 day patch with a 3.1% pullback, adding up to a 44.5% gain over the past year. Recent gains have largely been driven by growing investor confidence in Halozyme Therapeutics drug delivery...
NasdaqGS:CTSH
NasdaqGS:CTSHIT

Cognizant’s Expanded Microsoft AI Alliance and New AI Labs Might Change The Case For Investing In Cognizant Technology Solutions (CTSH)

Cognizant recently announced a series of multi-year agreements, including an AI-focused partnership with Microsoft, new AI-driven BPaaS and IT modernization deals with Bupa Hong Kong, ERIKS, and BayWa, alongside the opening of an India AI Lab and Cognizant Moment Studio in Bengaluru to deepen applied AI research and innovation. Together, these moves highlight how Cognizant is integrating agentic AI and sector-specific platforms into core client workflows, aiming to reposition itself as an...
NYSE:VG
NYSE:VGOil and Gas

Venture Global (VG): Reassessing Valuation After a Sharp Short-Term Rebound and Steep Year-to-Date Decline

Venture Global (VG) has quietly turned into a roller coaster for investors, with the stock jumping 4% in a day but still sitting deeply red over the past 3 months and year to date. See our latest analysis for Venture Global. That sharp 1 day and 7 day share price return rebound comes after months of heavy selling, with the 90 day and year to date share price returns still pointing to fading momentum as investors reassess both growth prospects and risk. Given how quickly sentiment can swing in...
NasdaqGM:STAA
NasdaqGM:STAAMedical Equipment

Is STAAR Surgical A Bargain After Years of Share Price Declines?

Wondering if STAAR Surgical at around $24 a share is a hidden bargain or a value trap? You are not alone, and that is exactly what we are going to unpack. The stock has been choppy, up 2.7% over the last week but down 13.6% over the past month. Despite being barely positive year to date at 0.4%, it is still sitting on steep losses of around 50% over three years and 70% over five. Those big swings are set against a backdrop of ongoing excitement around implantable Collamer lenses and the...
NasdaqGS:LAES
NasdaqGS:LAESSemiconductor

Is SEALSQ (LAES) Quietly Repositioning as a Post‑Quantum Cybersecurity Platform Play?

SEALSQ’s recently announced partnership with Airmod delivered a production-ready, open-source-enabled middleware stack built on SEALSQ Secure DevKits to speed deployment of quantum-resistant IoT devices, alongside appointing industry veteran Rolf Gobet to lead its Geneva Quantum Center of Excellence within the Europe-focused Quantum Corridor initiative. Together, the Airmod collaboration and Gobet’s leadership role highlight SEALSQ’s push to offer end-to-end post-quantum cybersecurity...